New mRNA vaccine aims to stop ovarian Cancer's return
NCT ID NCT07665515
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This early-stage trial tests a new mRNA cancer vaccine called CryptiVax-1001 in 50 women with advanced ovarian cancer. The vaccine is designed to train the immune system to recognize and attack cancer cells, potentially delaying or preventing the cancer from coming back. The main goal is to check safety and side effects, but researchers will also look at how well the vaccine activates the immune system.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CryptiVax-1001 (mRNA cancer vaccine)
What this could lead to
If it works, this vaccine could help delay or prevent ovarian cancer from returning after standard treatment.
What could go wrong
This is an early phase 1 trial with only 50 people, so it is too soon to know if it works. The main goal is safety, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beatson West of Scotland Cancer Centre
NOT_YET_RECRUITINGGlasgow, G12 0YN, United Kingdom
-
Cambridge University Hospitals NHS Foundation Trust - Addenbrookes Hospital
NOT_YET_RECRUITINGCambridge, CB2 0QQ, United Kingdom
-
Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital
NOT_YET_RECRUITINGLondon, SE1 9RT, United Kingdom
-
Lancashire Teaching Hospitals NHS Foundation Trust - Royal Preston Hospital
NOT_YET_RECRUITINGPreston, PR2 9HT, United Kingdom
-
Royal Marsden NHS Foundation Trust - Institute of Cancer Research
RECRUITINGSutton, SM2 5PT, United Kingdom
-
Royal Marsden NHS Foundation Trust - Royal Marsden Hospital
RECRUITINGLondon, SW3 6JJ, United Kingdom
-
St. James's University Hospital
NOT_YET_RECRUITINGLeeds, LS9 7TF, United Kingdom
-
The University of Edinburgh - Western General Hospital - Edinburgh Cancer Research Centre
NOT_YET_RECRUITINGEdinburgh, EH4 2XR, United Kingdom
-
University College London Hospitals NHS Foundation Trust - Cancer Clinical Trials Unit
RECRUITINGLondon, NW1 2PG, United Kingdom
-
University Hospitals of Leicester NHS Trust -Leicester Royal Infirmary
RECRUITINGLeicester, LE2 7LX, United Kingdom